keyword
MENU ▼
Read by QxMD icon Read
search

HPV vaccines safety

keyword
https://www.readbyqxmd.com/read/29044769/human-papillomavirus-vaccination-of-adult-women-and-risk-of-autoimmune-and-neurological-diseases
#1
A Hviid, H Svanström, N M Scheller, O Grönlund, B Pasternak, L Arnheim-Dahlström
BACKGROUND: Since 2006, human papillomavirus (HPV) vaccines have been introduced in many countries worldwide. Whilst safety studies have been reassuring, focus has been on the primary target group, the young adolescent girls. However, it is also important to evaluate safety in adult women where background disease rates and safety issues could differ significantly. OBJECTIVE: We took advantage of the unique Danish and Swedish nationwide healthcare registers to conduct a cohort study comparing incidence rate ratios (RRs) of 45 preselected serious chronic diseases in quadrivalent HPV (qHPV)-vaccinated and qHPV-unvaccinated adult women 18-44 years of age...
October 18, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28986659/hpv-vaccination-in-japan-results-of-a-3-year-follow-up-survey-of-obstetricians-and-gynecologists-regarding-their-opinions-toward-the-vaccine
#2
Masaaki Sawada, Yutaka Ueda, Asami Yagi, Akiko Morimoto, Ruriko Nakae, Reisa Kakubari, Hazuki Abe, Tomomi Egawa-Takata, Tadashi Iwamiya, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Tadashi Kimura
BACKGROUND: In Japan, the cervical cancer preventative HPV vaccination rate has dramatically declined, directly as a result of repeated broadcasts of so-called adverse events and the resulting suspension of the government's recommendation. Our previous survey of obstetricians and gynecologists in Japan regarding their opinions toward HPV vaccination revealed that these key specialists were as negatively influenced by the reports of purported negative events as were the general population...
October 6, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28986092/population-based-hpv-vaccination-programmes-are-safe-and-effective-2017-update-and-the-impetus-for-achieving-better-global-coverage
#3
REVIEW
Julia M L Brotherton, Paul N Bloem
Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that prophylactic HPV vaccines are immunogenic and effective against targeted-type HPV infections and type-specific genital lesions, including high-grade cervical intraepithelial neoplasia (CIN), when administered prior to HPV infection. There is good evidence that HPV vaccines are safe in population usage, with the most frequent adverse event being injection-site reactions...
September 6, 2017: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28984053/ten-year-immune-persistence-and-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-females-vaccinated-at-15-55%C3%A2-years-of-age
#4
Tino F Schwarz, Andrzej Galaj, Marek Spaczynski, Jacek Wysocki, Andreas M Kaufmann, Sylviane Poncelet, Pemmaraju V Suryakiran, Nicolas Folschweiller, Florence Thomas, Lan Lin, Frank Struyf
Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The duration of protection against HPV-16/18 from prophylactic vaccination remains unknown. We investigated the 10-year immune response and long-term safety profile of the HPV-16/18 AS04-adjuvanted vaccine (AS04-HPV-16/18 vaccine) in females aged between 15 and 55 years at first vaccination. Females who received primary vaccination with three doses of AS04-HPV-16/18 vaccine in the primary phase-III study (NCT00196937) were invited to attend annual evaluations for long-term immunogenicity and safety...
October 5, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28970457/pharmacists-attitudes-and-perceived-barriers-to-human-papillomavirus-hpv-vaccination-services
#5
Tessa J Hastings, Lindsey A Hohmann, Stuart J McFarland, Benjamin S Teeter, Salisa C Westrick
Use of non-traditional settings such as community pharmacies has been suggested to increase human papillomavirus (HPV) vaccination uptake and completion rates. The objectives of this study were to explore HPV vaccination services and strategies employed by pharmacies to increase HPV vaccine uptake, pharmacists' attitudes towards the HPV vaccine, and pharmacists' perceived barriers to providing HPV vaccination services in community pharmacies. A pre-piloted mail survey was sent to 350 randomly selected community pharmacies in Alabama in 2014...
August 7, 2017: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/28969653/association-between-parent-attitudes-and-receipt-of-human-papillomavirus-vaccine-in-adolescents
#6
Jeffrey J VanWormer, Casper G Bendixsen, Elizabeth R Vickers, Shannon Stokley, Michael M McNeil, Julianne Gee, Edward A Belongia, Huong Q McLean
BACKGROUND: Human papillomavirus (HPV) vaccine coverage rates remain low. This is believed to reflect parental hesitancy, but few studies have examined how changes in parents' attitudes impact HPV vaccine uptake. This study examined the association between changes in parents' vaccine attitudes and HPV vaccine receipt in their adolescent children. METHODS: A baseline and 1-year follow-up survey of HPV vaccine attitudes was administered to parents of 11-17 year olds who had not completed the HPV vaccine series...
October 2, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28950675/cervical-cancer-prevention-through-hpv-vaccination-in-low-and-middle-income-countries-in-asia
#7
Zheng Quan Toh, Paul V Licciardi, Fiona M Russell, Suzanne M Garland, Tsetsegsaikhan Batmunkh, Edward K Mulholland
Cervical cancer is ranked the first or second most common cancer in women of low- and middle-income countries (LMICs) in Asia. Cervical cancer is almost exclusively caused by human papillomavirus (HPV), and majority of the cases can be prevented with the use of HPV vaccines. The HPV vaccines have demonstrated high vaccine efficacies against HPV infection and cervical cancer precursors in clinical and post-marketing studies, and are in use in most high-income countries. However, their use in LMICs are limited mainly due to the high costs and logistics in delivering multiple doses of the vaccine...
September 27, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28935469/risk-of-guillain-barr%C3%A3-syndrome-following-quadrivalent-human-papillomavirus-vaccine-in-the-vaccine-safety-datalink
#8
Julianne Gee, Lakshmi Sukumaran, Eric Weintraub
OBJECTIVE: Describe the Vaccine Safety Datalink's (VSD) Guillain Barré Syndrome (GBS) surveillance following quadrivalent HPV vaccine (4vHPV) from 2006 through 2015. METHODS: Among 4vHPV vaccinated persons aged 9-26, ICD-9 coded GBS was identified in VSD's electronic data. Medical records were reviewed and adjudicated to confirm GBS. We calculated incidence rates of confirmed GBS within 1-42days following 4vHPV with a one-sided 95% confidence interval. RESULTS: Following 2,773,185 4vHPV doses, we confirmed 1 case of GBS in a male and no cases among females...
October 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28933635/factors-involved-in-human-papillomavirus-hpv-vaccine-hesitancy-among-women-in-the-south-east-asian-region-sear-and-western-pacific-region-wpr-a-scoping-review
#9
Diviya Santhanes, Che Pui Wong, Yan Ye Yap, Saw Pui San, Nathorn Chaiyakunapruk, Tahir Mehmood Khan
A scoping review was performed to identify factors that may lead to human papillomavirus (HPV) vaccine hesitancy among women in low- and middle-income countries in South East Asian Region (SEAR) and Western Pacific Region (WPR). A systematic search of English and non-English articles using Pubmed, EMBASE, PsycINFO, Cochrane, MEDLINE, and CINAHL plus was conducted. Only 63 studies conducted in SEAR and WPR were included from inception until December 2016. Results of these studies have shown that poor awareness and knowledge of practices on cervical cancer prevention was evident in both SEAR and WPR...
September 21, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28886907/final-efficacy-immunogenicity-and-safety-analyses-of-a-nine-valent-human-papillomavirus-vaccine-in-women-aged-16-26-years-a-randomised-double-blind-trial
#10
Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleton, Dorothy J Wiley, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark H Stoler, Jack Cuzick, Suzanne M Garland, Susanne K Kjaer, Oliver M Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C Roberts, Christine Shields, Alain Luxembourg
BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. We aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and antibody responses over 5 years...
September 5, 2017: Lancet
https://www.readbyqxmd.com/read/28875439/current-status-and-future-prospects-for-human-papillomavirus-vaccines
#11
REVIEW
Hyoung Jin Kim, Hong-Jin Kim
Cervical cancer is the fourth most frequent cancer among women worldwide. Human papillomaviruses (HPVs) cause almost all cervical cancers in low-income countries. Three prophylactic HPV virus-like particle-based vaccines have been licensed to date, and they have all shown high efficacy and reliable safety profiles. However, isolated safety issues have resulted in a reluctance to use these vaccinations. In addition, the high prices of the vaccinations have caused the inequitable distribution of the vaccine: the prices are unaffordable for low-income countries...
September 5, 2017: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/28863867/results-on-exposure-during-pregnancy-from-a-pregnancy-registry-for-as04-hpv-16-18-vaccine
#12
Marta López-Fauqued, Julia Zima, Maria-Genalin Angelo, Jens-Ulrich Stegmann
OBJECTIVE: To assess pregnancy outcomes after exposure to AS04-HPV-16/18 vaccine (Cervarix, GSK, Belgium) prior to, or during pregnancy, as reported to a pregnancy registry. METHODS: A pregnancy exposure registry was established to collect data in the United Kingdom and the United States. Exposure was defined as vaccination with AS04-HPV-16/18 within 60days before the estimated conception date and delivery. Reporting was voluntary. RESULTS: Between September 2007 and November 2015, 306 pregnancy exposure reports were received of which 181 were prospective, evaluable reports...
September 25, 2017: Vaccine
https://www.readbyqxmd.com/read/28854964/perceptions-of-human-papillomavirus-vaccination-of-adolescent-schoolgirls-in-western-uganda-and-their-implications-for-acceptability-of-hpv-vaccination-a-qualitative-study
#13
Andrew Kampikaho Turiho, Elialilia Sarikieli Okello, Wilson Winstons Muhwezi, Anne Ruhweza Katahoire
BACKGROUND: Human papillomavirus (HPV) vaccination has been perceived in diverse ways some of which encourage its uptake while others could potentially deter its acceptability. This study explored community member's perceptions about HPV vaccination in Ibanda district and the implications of the perceptions for acceptability of HPV vaccination. The study was conducted following initial vaccination of adolescent schoolgirls in the district between 2008 and 2011. METHODS: This qualitative study employed focus group discussions (FGDs) and key informant interviews (KIIs)...
August 30, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28845336/elimination-of-cancer-health-disparities-through-the-acceleration-of-hpv-vaccines-and-vaccinations-a-simplified-version-of-the-president-s-cancer-panel-report-on-hpv-vaccinations
#14
Eva McGhee, Hill Harper, Adaku Ume, Melanie Baker, Cheick Diarra, John Uyanne, Sebhat Afework, Keosha Partlow, Lucy Tran, Judith Okoro, Anh Doan, Karen Tate, Mechelle Rouse, Meidrah Tyler, Kamilah Evans, Tonya Sanchez, Ishmum Hasan, Enijah Smith-Joe, Jasmine Maniti, Liliana Zarate, Camille King, Antoinette Alugbue, Chiamaka Opara, Bileko Wissa, Joanne Maniti, Roland Pattillo
The human papillomavirus (HPV) is a major public health concern affecting both females and males. HPV is associated with cervical, anal, head and neck cancers. About 99% of all cervical cancers are related to HPV. HPV vaccines, Gardasil, Cervarix, and Gardasil 9 are used in the primary prevention of HPV related cancers. Gardasil and Gardasil 9 are available for use in both females and males ages 9 to 26, while Cervarix is available for females ages 9 to 25. Gardasil 9 was approved by the FDA for prevention against additional HPV types...
June 2017: Journal of Vaccines & Vaccination
https://www.readbyqxmd.com/read/28842066/human-papillomavirus-vaccination-what-are-the-reasons-for-nonvaccination-among-u-s-adolescents
#15
Erika L Thompson, Brittany L Rosen, Cheryl A Vamos, Mika Kadono, Ellen M Daley
PURPOSE: Human papillomavirus (HPV) vaccination is recommended for 11- to 12-year-old U.S. adolescents. Unfortunately, HPV vaccine rates have been suboptimal. Parents are key decision agents regarding their adolescents' health; thus, it is necessary to understand their reasons for not vaccinating their adolescents. The purpose of this study was to compare parents' primary reasons for non-HPV vaccination by calendar year, sex of the child, and level of vaccine hesitancy. METHODS: The National Immunization Survey-Teen 2012-2015 was subset to parents who did not intend for their adolescent to receive the HPV vaccine in the next 12 months (N = 59,897)...
September 2017: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/28834689/association-of-physicians-perceived-barriers-with-human-papillomavirus-vaccination-initiation
#16
Albert J Farias, Lara S Savas, Maria E Fernandez, Sharon P Coan, Ross Shegog, C Mary Healy, Erica Lipizzi, Sally W Vernon
Physician recommendation is a strong predictor of vaccine uptake, however their perceived barriers may prevent vaccination. Therefore, we determined the association between physicians' perceived barriers to HPV vaccination and vaccination initiation. We surveyed pediatricians in a large network of clinics in Houston, Texas to assess their perceived barriers to vaccinating adolescents. We combined survey data with electronic medical records to determine HPV vaccination initiation over a 12-month study period (July 2014-June 2015)...
August 20, 2017: Preventive Medicine
https://www.readbyqxmd.com/read/28822674/increasing-parental-knowledge-related-to-the-human-papillomavirus-hpv-vaccine
#17
Joseph J Cipriano, Robert Scoloveno, Angela Kelly
INTRODUCTION: The purposes of this study were to evaluate parental attitudes toward general vaccination protocols and increase parental knowledge of the human papilloma virus (HPV) vaccine. METHODS: A nonprobability convenience sample (N = 75) using a pre-/postintervention study design was conducted in a pediatric office in southern New Jersey. The Parental Attitudes Module measured the general disposition toward having children receive any type of vaccine. The HPV Knowledge Survey was a second tool used to specifically measures knowledge of the HPV vaccine...
August 16, 2017: Journal of Pediatric Health Care
https://www.readbyqxmd.com/read/28812030/safety-of-human-papillomavirus-9-valent-vaccine-a-meta-analysis-of-randomized-trials
#18
REVIEW
Ana Paula Ferreira Costa, Ricardo Ney Oliveira Cobucci, Janine Medeiros da Silva, Paulo Henrique da Costa Lima, Paulo César Giraldo, Ana Katherine Gonçalves
Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28801154/progress-in-prophylactic-human-papillomavirus-hpv-vaccination-in-2016-a-literature-review
#19
Polona J Maver, Mario Poljak
Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate screening, it has the potential to dramatically reduce cervical cancer incidence and even eradicate it. Following extensive evaluations in clinical trials, the first decade of routine HPV vaccine use provides overwhelming evidence of the vaccines' safety and their real-life effectiveness. In 2016, further clinical trials showed high vaccine efficacy in adult women, especially those that were HPV DNA-negative at baseline, and indicated possible protection from HPV-related diseases after treatment of precancerous cervical lesions...
August 8, 2017: Vaccine
https://www.readbyqxmd.com/read/28796684/maternal-and-infant-outcomes-after-human-papillomavirus-vaccination-in-the-periconceptional-period-or-during-pregnancy
#20
Heather S Lipkind, Gabriela Vazquez-Benitez, James D Nordin, Paul A Romitti, Allison L Naleway, Nicola P Klein, Rulin C Hechter, Michael L Jackson, Simon J Hambidge, Grace M Lee, Lakshmi Sukumaran, Elyse O Kharbanda
OBJECTIVE: To evaluate whether quadrivalent human papillomavirus vaccine (4vHPV) administered during the periconceptional period or during pregnancy was associated with increased risks for adverse obstetric events, adverse birth outcomes, or selected major structural birth defects. METHODS: We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccine Safety Datalink. Insured women 13-27 years old with singleton pregnancies and a live birth from January 1, 2007, through September 1, 2013, who received 4vHPV during the periconceptional period (2 weeks before to 2 weeks after their last menstrual period), during pregnancy, or during both periods combined were compared with women who had a live birth during the same time period and received 4vHPV 4-18 months before their last menstrual period...
September 2017: Obstetrics and Gynecology
keyword
keyword
102610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"